Subject Category Author Posted Rep. last R. [asc] Views
Study Per­for­mance roody 2005-11-18 10:03 0   8,297
Regulatives / Guidelines Helmut 2005-11-19 18:20 0   8,110
Regulatives / Guidelines shiv 2006-01-25 06:39 3 2006-01-27 13:00 15,211
Regulatives / Guidelines SIVAPRASAD 2006-02-06 04:57 1 2006-02-06 05:22 9,260
Design Issues Essar 2006-02-28 11:40 3 2006-03-01 11:15 11,288
Bioanalytics Ma. Teresa M.Mercado 2006-03-31 04:49 1 2006-03-31 10:50 8,349
Bioanalytics devender_naik 2006-04-27 10:12 1 2006-04-27 09:59 8,165
Regulatives / Guidelines devender_naik 2006-05-06 09:56 1 2006-05-06 08:21 8,250
Design Issues chandramohan 2006-05-06 10:58 1 2006-05-06 09:48 7,742
Study Per­for­mance dinesh 2006-05-06 12:47 3 2006-05-06 12:58 9,956
Regulatives / Guidelines Arulsingh Jayaraman 2006-04-06 12:54 2 2006-05-08 17:41 8,684
Study Per­for­mance devender_naik 2006-05-08 06:00 1 2006-05-08 17:49 7,779
Regulatives / Guidelines joyjac 2006-05-09 07:45 3 2006-05-10 06:22 9,585
Regulatives / Guidelines esreddy 2006-04-28 08:14 2 2006-05-10 09:36 9,359
Regulatives / Guidelines patel_prakash79 2006-05-19 07:56 1 2006-05-19 11:25 13,017
UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
23 visitors (0 registered, 23 guests [including 16 identified bots]).
Forum time: 23:17 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5